Patents Examined by Kristina M Hellman
  • Composition for improving or preventing nonalcoholic fatty liver
    Patent number: 11207371
    Abstract: An object of the present invention is to provide a composition for preventing or improving fat deposition on the liver in spite of the alcohol intake history of a level that a liver disease is not caused. The inventors found that glutathione has an effect of preventing or improving fat deposition on the liver, which is not caused by alcohol, and completed the present invention. Among nonalcoholic fat diseases, the present invention is particularly effective in an early stage of the treatment or in a case where treatment for another disease is not performed.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: December 28, 2021
    Assignees: KOHJIN LIFE SCIENCES CO., LTD., PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, SAGA UNIVERSITY
    Inventors: Takaomi Kessoku, Atsushi Nakajima, Yoshio Sumida, Yuichiro Eguchi, Susumu Saito, Yusuke Sauchi
  • Methods and compositions for treating melanoma
    Patent number: 11208468
    Abstract: Compositions and methods for treating melanoma are provided. Compositions include BRAFV600E-based peptides, alone or admixed with T helper peptides. Other compositions include nucleic acid sequences encoding the BRAFV600E-based peptides, alone or admixed with nucleic acid sequences T helper peptides. Dendritic cells pretreated with the BRAFV600E-based peptides, alone or admixed with T helper peptides, are also provided. These compositions are useful to treat melanoma, optionally co-administered with antibodies to checkpoint inhibitors or molecules that mimic the action of such antibodies.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: December 28, 2021
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Rajasekharan Somasundaram, Meenhard Herlyn, Dorothee Herlyn
  • Compositions and methods for modulating ciliogenesis
    Patent number: 11207369
    Abstract: Disclosed herein are methods for modifying ciliogenesis in one or more cells of a subject, the method comprising administering to the subject an effective amount of a composition comprising a Notch signaling inhibitor, wherein the modification results in an increase in a number of cilia, an increase in a length of cilia, and/or an increase in a beat frequency of cilia as compared to a control. Also disclosed herein are methods for modifying ciliogenesis in one or more cells of a subject, the method comprising administering to the subject from 0.1 ?g/kg to 100 g/kg of a Notch signaling inhibitor. In some embodiments, the methods can be used to treat Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Asthma, Primary Ciliary Dyskinesia (PCD), Cystic Fibrosis (CF), or hydrocephalus.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: December 28, 2021
    Assignee: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Maliha Zahid, Cecilia Wen Ya Lo
  • Pharmaceutical composition for preventing or treating neovascular disease, containing collagen type i and pigment epithelium derived factor peptide as active ingredients
    Patent number: 11197918
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neovascular disease, including a collagen and a 34-mer pigment epithelium derived factor (PEDF) peptide as an active ingredient, more specifically, the combined administration of the collagen type I and the 34-mer pigment epithelium derived factor peptide increases the short antiangiogenic activity cycle of the PEDF and extends the dosage range of the PEDF to solve the discomfort and the side effects accordingly due to the conventional frequent injections and thus it can be applied as a therapeutic agent for various neovascular diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: December 14, 2021
    Assignee: NexThera Co., Ltd.
    Inventors: Sea Gwang Park, Kug Hwan Roh, Hyun Woong Kim, Sung Jae Park
  • Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
    Patent number: 11191818
    Abstract: The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). The disclosure provides A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13) or a composition comprising ADAMTS13 for treating, ameliorating, and/or preventing the VOC, or for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from ALI and/or ARDS.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: December 7, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Bruce Ewenstein, Brahm Goldstein, Bernhard Majer, Paolo Rossato, Friedrich Scheiflinger, Marietta Turecek
  • Solid-phase support comprising IgG-binding peptide, and method for separating IgG
    Patent number: 11186613
    Abstract: The present invention provides an IgG-binding peptide which can be used for the purification of IgG and has excellent stability, e.g., alkali stability. The present invention also provides a method for purifying IgG using the IgG-binding peptide. Specifically, the present invention relates to a solid-phase support including an IgG-binding peptide, an IgG separation column including the solid-phase support, a kit including the solid-phase support or the column, and a method for purifying IgG using the solid-phase support or the column.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: November 30, 2021
    Assignees: Kagoshima University, Daicel Corporation
    Inventors: Yuji Ito, Seiichi Uchimura
  • Antimicrobial peptides based on CMAP27
    Patent number: 11186619
    Abstract: The invention concerns derivatives of CMAP27, which have a good antimicrobial activity and a low haemolytic activity as compared to the wild-type CMAP27 peptide. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. Further comprised in the invention is the use of CMAP27 and/or its derivatives as adjuvant.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: November 30, 2021
    Assignee: Universiteit Utrecht Holding B.V.
    Inventors: Floris Jacob Bikker, Albert van Dijk, Rosalia Mars-Groenendijk, Edwin Johannes Adrianus Veldhuizen, Desiree van der Kleij, Hendrik Haagsman, Elisabeth Margaretha Molhoek
  • Methods and compositions for topical delivery for skin care
    Patent number: 11160745
    Abstract: The present invention provides a topical composition for application to a keratinous tissue comprising a cosmetically or pharmaceutically acceptable carrier; one or more selected from potassium, zinc, calcium, rubidium disposed in the cosmetically or pharmaceutically acceptable carrier; and one or more peptides disposed in the cosmetically or pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: November 2, 2021
    Inventor: Gregory P. Pilant
  • Use of peptides to stimulate the immune system
    Patent number: 11154587
    Abstract: Methods for treating immunodeficiencies are provided using peptide-based compounds.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: October 26, 2021
    Assignee: DIACCURATE
    Inventors: Blanche Tamarit, Jacques Theze
  • SIRPalpha-41BBL fusion protein and methods of use thereof
    Patent number: 11130796
    Abstract: SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRP1alpha-41BBL fusion protein, host-cells expressing the SIRP1alpha-41BBL fusion protein and methods of use thereof.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: September 28, 2021
    Assignee: KAHR Medical Ltd.
    Inventors: Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
  • Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides
    Patent number: 11124559
    Abstract: Described herein is the use of elastin-like polypeptides to generate hemoglobin-based oxygen carriers as a means of preventing and treating conditions caused by blood loss or anemia, for example, hemorrhagic shock. Elastin-like polypeptides are capable of creating therapeutically functional fusion proteins through genetic engineering with a therapeutic agent, for example, hemoglobin and biologic equivalent thereof. Specific forms of these fusion proteins have the ability to form into spherical nanoparticles possessing a therapeutically agent at their core. This provides a unique basis for employing elastin-like polypeptides as hemoglobin carriers in the manufacture of blood substitutes.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: September 21, 2021
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Jordan Tremaine Despanie, Hao Guo, John Andrew MacKay
  • TLR9 targeted therapeutics
    Patent number: 11123435
    Abstract: Disclosed are compositions and methods for targeted treatment of cancers, such as TLR9-expressing cancers. In particular, molecules containing a TLR9 targeting ligand, such as a CpG oligodeoxynucleotide, that target lytic peptides to TLR9-expressing malignant cells are disclosed.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: September 21, 2021
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South Florida
    Inventors: Alan List, Sheng Wei, Mark L. McLaughlin
  • Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
    Patent number: 11116820
    Abstract: In one aspect, methods of treating hyperinsulinemic hypoglycemia comprising administration of an effective amount of a derivative of an exendin-4 peptide are provided. In some embodiments, the method comprises subcutaneously administering to a patient having hyperinsulinemic hypoglycemia a therapeutically effective amount of exendin(5-39).
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: September 14, 2021
    Assignee: EIGER BIOPHARMACEUTICALS, INC.
    Inventor: Xiaofeng Xiong
  • Esculentin 1a derivatives and uses thereof
    Patent number: 11110195
    Abstract: Provided herein are synthetic antibacterial peptides that have a sequence at least 80% identical to a sequence shown in SEQ ID NO: 2 or the diastereomer thereof with a sequence shown in SEQ ID NO: 3 or pharmaceutical compositions thereof. Also provided are methods for stimulating wound healing via the synthetic antibacterial peptides and for forming an antimicrobial coating on contact lenses. In addition a device is provided that has a surface with a coating of the synthetic antibacterial peptides.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: September 7, 2021
    Assignees: UNIVERSITY OF HOUSTON SYSTEM, UNIVERSITA' DEGLI STUDI DI ROMA LA SAPIENZA
    Inventors: Alison McDermott, Maria Luisa Mangoni
  • Bicyclic peptide ligands specific for MT1-MMP
    Patent number: 11103591
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP). The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: August 31, 2021
    Assignee: BicycleRD Limited
    Inventors: Daniel Paul Teufel, Catherine Lucy Stace, Silvia Pavan, Edward Walker, Leonardo Baldassarre
  • Pharmaceutical compositions and methods
    Patent number: 11103559
    Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: August 31, 2021
    Assignee: Tyme, Inc.
    Inventor: Steven Hoffman
  • Applications of mussel adhesive protein product in treatment and prevention of diseases related to melanin
    Patent number: 11090360
    Abstract: Disclosed are applications of a mussel adhesive protein or preparations thereof in treatment and prevention of diseases related to melanin. Specifically disclosed are applications of a mussel adhesive protein or preparations thereof in treatment and prevention of pigmentations such as chloasma, freckles, melanosis, applications in skin cancers represented by melanoma, and applications in treatment of pigmentation possibly caused by skin diseases or drugs.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: August 17, 2021
    Assignee: JIANGYIN BENGT I. SAMUELSSON INSTITUTE OF LIFE SCIENCE CO., LTD.
    Inventors: Jan Christer Janson, Min Gao
  • Peptides having reduced toxicity that stimulate cholesterol efflux
    Patent number: 11091529
    Abstract: The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimers Disease or frontotemporal dementia.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: August 17, 2021
    Assignee: The Regents of the University of California
    Inventors: John K. Bielicki, Jan Johansson
  • Protease-activated receptor-2 modulators
    Patent number: 11091533
    Abstract: Provided herein are peptides comprising a mutated fragment of a wild-type protease-activated receptor-2 (PAR2). The peptides comprising a hydrophobic moiety can penetrate the cell membrane and act as an antagonist of PAR2. Also provided herein are compositions and cells comprising the peptides and methods of using the peptides.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: August 17, 2021
    Assignee: Oasis Pharmaceuticals, LLC
    Inventor: Richard Looby
  • Soy-derived bioactive peptides for use in compositions and methods for wound healing, tissue engineering, and regenerative medicine
    Patent number: 11077169
    Abstract: Compositions and methods for the promotion of wound healing and tissue regeneration are described. The compositions and methods make use of water-soluble soy protein isolates (WSsoy), Fraction 5, Fraction 9, and/or bioactive peptide components of soy protein isolates. The invention also relates to the unexpected discovery that purified WSsoy forms gel-like matrices when suspended within certain concentration ranges in an aqueous environment. The compositions of the invention comprising WSsoy promote natural healing and have a low risk profile.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: August 3, 2021
    Assignee: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Peter I. Lelkes, Yah-El H. Har-el, Cezary Marcinkiewicz, Philip Lazarovici, Sogol Moaiyed Baharlou, Jonathan A. Gerstenhaber